Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed-combination timolol + dorzolamide + brimonidine versus Combigan-D in open-angle glaucoma or ocular hypertension
ISRCTN11060993Phase 3Completed
- Sponsor
- Laboratorios Sophia
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of timolol, dorzolamide and brimonidine in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Laboratorios Sophia. Primary endpoint: Intraocular pressure. Started Jan 2009; status: completed.
02
Drugs
timololdorzolamidebrimonidine
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on ISRCTN11060993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11060993.